# 바이오스페이스 일일 뉴스 리포트 - 2026년 02월 20일


## 주요 헤드라인

1. **Redefining Obesity Treatment Beyond GLP-1 Limits (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/redefining-obesity-treatment-beyond-glp-1-limits>

2. **Redefining Obesity Treatment Beyond GLP-1 Limits (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/redefining-obesity-treatment-beyond-glp-1-limits>

3. **Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’ (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/cassidy-names-areas-of-improvement-for-fdas-regulatory-black-box>

4. **Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/muscle-preservation-tolerability-and-alternative-administration-routes-define-obesitys-drug-future>

5. **Opinion (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/opinion-extending-scientific-rigor-from-bench-to-boardroom>

6. **Opinion (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/opinion-extending-scientific-rigor-from-bench-to-boardroom>

7. **Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/early-stage-biotechs-suffer-in-2025-as-vc-shuns-risk-pitchbook>


---
*2026년 02월 20일 바이오스페이스 뉴스 피드에서 생성된 리포트*